Phibro Animal Health Corp

Phibro Animal Health Corp(PAHC)の株式分析

$39.340

+0.527 (+1.34%)終値時点

Loading chart…
高値
39.810
始値
39.120
出来高加重平均価格
39.23
出来高
184.84K
時価総額
696.66M
安値
38.530
売買代金
7.25M
EV/EBITDA(TTM)
10.23

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

www.pahc.com

AI分析 of Phibro Animal Health Corp (PAHC)

買い

Phibro Animal Health Corp is a good buy right now due to its strong recent financial performance, with a 37% increase in adjusted net income for Q4 2026 reaching $35 million, and a projected earnings per share for 2027 between $2.98 and $3.22, indicating continued profitability growth. The current price of $38.82 is below the analyst price target of $44, suggesting a potential upside of approximately 13.5%. However, the main risk is the debt to equity ratio, which stands at 190.10%, indicating a high level of leverage that could impact financial stability if not managed carefully.

アナリスト評価(6)

上値余地 +20.74%
売り
1 買い
2 中立
3 売り
現在: 39.34
安値
45.00
平均
47.50
高値
50.00

Citi

2026-05-14

目標株価

$44

中立

Citi

2026-05-13

目標株価

$44

中立

Citi

2026-04-15

目標株価

$62

中立

Morgan Stanley

2026-02-06

目標株価

$49

Equal Weight

JPMorgan

2025-11-07

目標株価

$50

オーバーウェイト

バリュエーション指標

Phibro Animal Health Corp(PAHC)の現在の予想PERは13.83で、5年平均は12.61です。

予想PER

適正
5年平均 P/E
12.61
現在のP/E
13.83
割高
14.88
割安
10.34

予想EV/EBITDA

割高
5年平均 EV/EBITDA
8.80
現在のEV/EBITDA
10.23
割高
10.04
割安
7.55

予想PSR

適正
5年平均 P/S
0.76
現在のP/S
0.97
割高
1.00
割安
0.53

PAHC を保有するクジラ

C

Castleknight Management LP

+ を保有PAHC

-7.34%

3か月リターン

イベントタイムライン

2026-08-26 (ET)

20:00:00

Salesforce Shares Rise 12.8% After Earnings Boost

16:30:00

Sees FY27 Revenue of $1.55B to $1.6B

16:30:00

Phibro Animal Health Q4 Revenue $396.7M Beats Expectations

2026-05-06 (ET)

16:50:00

Raises FY26 Revenue Outlook to $1.46B-$1.5B

16:40:00

Phibro Animal Health Reports Q3 Revenue of $383.5M

ニュース

PAHC のよくある質問 — Alphio AI が回答

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phibro Animal Health Corp is a good buy right now due to its strong recent financial performance, with a 37% increase in adjusted net income for Q4 2026 reaching $35 million, and a projected earnings per share for 2027 between $2.98 and $3.22, indicating continued profitability growth. The current price of $38.82 is below the analyst price target of $44, suggesting a potential upside of approximately 13.5%. However, the main risk is the debt to equity ratio, which stands at 190.10%, indicating a high level of leverage that could impact financial stability if not managed carefully.

6 analysts cover PAHC: 1 rate it Buy, 2 Hold and 3 Sell. The average price target is 47.50.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める